Get Your Personalized Supplement StackSupplement Stack Quiz

Vitamina K2

Also known as: Vitamin K2, MK-4, MK-7, 2-methyl-1,4-naphthoquinone derivatives, Menaquinone

Overview

Vitamin K2, also known as menaquinone, is a fat-soluble vitamin essential for various physiological processes, primarily blood clotting and bone metabolism. Unlike Vitamin K1 (phylloquinone), found in green leafy vegetables, K2 is predominantly found in fermented foods like natto, certain animal products, and is synthesized by gut bacteria. It exists in various forms, with MK-4 and MK-7 being the most common and well-researched subtypes. Supplementation with Vitamin K2 is primarily utilized for its significant role in promoting bone health, particularly in preventing and managing osteoporosis, and for its potential to improve cardiovascular health by inhibiting vascular calcification. It is characterized by a longer half-life and superior bioavailability compared to Vitamin K1, making it more effective in activating key vitamin K-dependent proteins crucial for bone mineralization and maintaining arterial flexibility. Research on Vitamin K2 is extensive, with high-quality evidence from numerous randomized controlled trials, systematic reviews, and meta-analyses supporting its benefits.

Benefits

Vitamin K2 offers several evidence-based benefits, primarily in bone and cardiovascular health. For bone mineral density (BMD), meta-analyses of randomized controlled trials (RCTs) show that Vitamin K2 supplementation significantly improves lumbar spine BMD in middle-aged and elderly populations, especially postmenopausal women, with reported mean differences of 1.0 to 2.0 percentage points compared to controls. This improvement contributes to a reduction in fracture incidence and enhanced bone strength by promoting osteocalcin carboxylation. In cardiovascular health, Vitamin K2 has been shown to slow the progression of coronary artery calcification (CAC) and reduce levels of inactive matrix Gla-protein (dp-ucMGP), a marker associated with vascular calcification risk. While its effects on other cardiovascular risk factors like lipids are generally non-significant, it may offer a modest improvement in insulin resistance (HOMA-IR). Postmenopausal women benefit most from Vitamin K2 for bone health due to their higher risk of osteoporosis, and individuals with chronic kidney disease or on hemodialysis may benefit from its vascular calcification attenuating properties. The bone density improvements are statistically significant and clinically relevant for osteoporosis management, while cardiovascular benefits are promising and warrant further investigation.

How it works

Vitamin K2 functions as a crucial cofactor for the enzyme gamma-glutamyl carboxylase. This enzyme is responsible for activating vitamin K-dependent proteins by carboxylating specific glutamate residues within their structure. In the skeletal system, Vitamin K2 activates osteocalcin, a protein that plays a vital role in binding calcium and facilitating its integration into the bone matrix, thereby enhancing bone mineralization. In the vascular system, it activates matrix Gla-protein (MGP), which is a potent inhibitor of soft tissue calcification, preventing calcium from depositing in arterial walls. The superior bioavailability and longer half-life of Vitamin K2, particularly the MK-7 form, lead to sustained plasma levels, ensuring prolonged biological activity and more effective activation of these critical proteins.

Side effects

Vitamin K2 supplementation is generally considered safe and well-tolerated, with a low incidence of adverse effects reported in clinical trials. Common side effects are rare, and no significant adverse effects have been consistently reported in high-quality randomized controlled trials. Uncommon and rare side effects are also not consistently documented, with hypersensitivity reactions being exceedingly rare. The primary safety concern for Vitamin K2 relates to its interaction with anticoagulant medications, specifically vitamin K antagonists like warfarin. Due to its role in blood clotting, Vitamin K2 can interfere with the action of these drugs, potentially reducing their effectiveness and increasing the risk of blood clots. Therefore, patients on warfarin or similar anticoagulants should avoid Vitamin K2 supplementation unless under strict medical supervision and with careful monitoring of their coagulation status. There are no specific contraindications for healthy individuals, and it is generally safe for elderly and postmenopausal women, provided they are not on anticoagulant therapy.

Dosage

The minimum effective dose of Vitamin K2 varies, but studies often utilize doses ranging from 45 mcg to 180 mcg per day, particularly for the MK-7 form. For optimal bone health benefits, a common and effective dosage range is 90–180 mcg/day of MK-7. While there is no established upper limit for Vitamin K2, doses up to 360 mcg/day have been safely used in clinical trials without reported adverse effects. It is recommended to take Vitamin K2 daily with meals, as its fat-soluble nature means that the presence of dietary fat enhances its absorption. The MK-7 form is generally preferred due to its longer half-life and sustained biological activity, although MK-4 is also effective but typically requires higher doses. Adequate Vitamin D status is also important, as it may synergistically enhance the bone health benefits of Vitamin K2.

FAQs

Is vitamin K2 safe for long-term use?

Yes, long-term supplementation with Vitamin K2 is generally considered safe, with no major adverse effects consistently reported in studies, making it suitable for prolonged use.

Can vitamin K2 be taken with vitamin D?

Yes, Vitamin K2 can be safely taken with Vitamin D. Their combined supplementation is common and may offer synergistic benefits for bone health, enhancing calcium utilization.

How soon can benefits be expected?

Improvements in bone mineral density typically become noticeable after 6 months or more of consistent supplementation, while potential vascular benefits may require even longer-term use.

Does vitamin K2 help with cardiovascular disease?

Evidence suggests Vitamin K2 can slow the progression of vascular calcification, a risk factor for cardiovascular disease. However, more extensive research is needed to confirm definitive cardiovascular outcome benefits.

Is vitamin K2 better than K1?

Yes, Vitamin K2 is generally considered superior to K1 due to its better bioavailability and significantly longer half-life, leading to more sustained and effective biological actions in the body.

Research Sources

https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.979649/full – This systematic review and meta-analysis of 10 RCTs found that Vitamin K2 supplementation significantly improved lumbar spine BMD and reduced fracture incidence in postmenopausal women. It highlights the high-quality evidence supporting bone benefits despite some heterogeneity in study designs.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11631259/ – This systematic review demonstrated Vitamin K2's superiority over K1 in improving lumbar spine BMD and osteocalcin carboxylation, particularly in postmenopausal women. It emphasized K2's longer half-life as a key factor for its enhanced efficacy in bone health.
https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1115069/full – This meta-analysis of 7 RCTs indicated that Vitamin K2 supplementation significantly slowed coronary artery calcification progression and reduced dp-ucMGP levels. It concluded that Vitamin K2 shows promise for vascular health, though further large-scale trials are needed to confirm these findings.
https://pubmed.ncbi.nlm.nih.gov/36033779/ – This study, likely a meta-analysis, supports the findings that Vitamin K2 improves lumbar spine BMD and reduces fracture risk, reinforcing the evidence for its role in osteoporosis management. It contributes to the understanding of K2's clinical significance in bone health.
https://pubmed.ncbi.nlm.nih.gov/38282652/ – This meta-analysis of 17 RCTs found that Vitamin K2 supplementation significantly reduced insulin resistance (HOMA-IR) but had no significant effect on lipid profiles or inflammatory markers. It suggests modest metabolic benefits of K2, but limited impact on other cardiovascular risk factors.